MHLW Grants NHI Listing To 23 Generic Makers For Daiichi Sankyo’s Levofloxacin
This article was originally published in PharmAsia News
The Ministry of Health, Labor and Welfare May 15 listed 318 generic drugs for the national health insurance price listing, including 23 companies listed for Daiichi Sankyo's antibacterial Cravit (levofloxacin). Those generic companies include Sawai Pharmaceutical, Nichi-Iko, Taiyo and Towa Pharmaceutical. The NHI also included 39 generic drugs for Daiichi Sankyo's hypertension drug Acecol (temocapril). Japan's major generic drug makers such as Sawai had 22 drugs listed, Nichi-Iko had 23 drugs, Taiyo had 17, Nipro Pharma had 15 and Towa got 14 drugs listed. The generic drug NHI price listing is conducted twice a year in Japan, in July and November. The July date this year was moved up to May. (Click here for more - Japanese language
You may also be interested in...
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.
In the age of coronavirus, human factors professionals are doing their best to find their way through the pandemic by putting unique twists on usability testing to see what works and what doesn’t in the new reality. That’s the topic of this week’s podcast.